Welcome to our dedicated page for PHARM news (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM stock.
Pharming Group N.V. (PHARM) is a biotechnology leader developing innovative therapies for rare diseases, including hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta syndrome (APDS). This page provides investors and healthcare professionals with direct access to the company's latest press releases and official announcements.
Track PHARM's progress through updates on clinical trials, regulatory milestones, and commercialization efforts for therapies like RUCONEST® and Joenja®. Our curated news feed ensures you stay informed about earnings reports, strategic partnerships, and market expansion initiatives without extraneous information.
Discover updates categorized for quick navigation, including product development breakthroughs, financial performance disclosures, and operational strategy refinements. All content is sourced directly from Pharming's verified communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to PHARM's evolving story in rare disease treatment. Check regularly for new developments that demonstrate the company's commitment to addressing unmet medical needs through biopharmaceutical innovation.
Pharming (PHARM) reported strong 3Q2025 results: total revenue +30% to US$97.3m, driven by RUCONEST® US revenue US$81.1m and Joenja® revenue US$15.1m. Operating profit rose 285% to US$15.8m and operating cash flow was US$32.0m for the quarter. Management raised full-year 2025 revenue guidance to US$365–375m. The FDA granted Priority Review of the leniolisib (Joenja) sNDA for ages 4–11 with a PDUFA date Jan 31, 2026. Organizational moves include a new CCO effective Jan 1, 2026, and a restructuring to cut G&A by ~US$10m annually with ~US$7m one-time costs.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) announced management will participate in the Jefferies Global Healthcare Conference in London on November 17-20, 2025. Fabrice Chouraqui, Chief Executive Officer, will take part in a Fireside Chat Q&A on Wednesday, November 19 at 10:00 GMT / 11:00 CET. A live webcast and replay will be available via the company website under Upcoming Events and News. Investors seeking one-to-one meetings or more details can contact Investor Relations at investor@pharming.com or coordinate through a Jefferies representative.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) will report preliminary unaudited Q3 2025 financial results and provide a business update on Thursday, November 6, 2025.
Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET / 07:30 ET. Investors must register in advance for the conference call or webcast; dial-in attendees will receive a unique PIN and only dial-in participants can ask questions. The webcast will be available on the company’s Investors/Financial Documents page and a replay will be posted shortly after the event.
Pharming (Euronext: PHARM; Nasdaq: PHAR) announced that 12 abstracts were accepted for presentation at the ACAAI 2025 Annual Scientific Meeting in Orlando, Florida, November 6-10, 2025.
Five posters cover new clinical, economic and comparative data for RUCONEST in on-demand hereditary angioedema (HAE). Seven posters present real-world effectiveness and pediatric Phase III results for Joenja (leniolisib) and explore pediatric and caregiver burden in APDS.
Selected poster dates/times are on November 7-9, 2025; all ePosters will be available online on ACAAI’s site to registered attendees starting November 6, 2025 at 08:00 EST.
Pharming (Euronext: PHARM; Nasdaq: PHAR) announced an organizational restructuring to accelerate growth and implement a previously disclosed G&A reduction plan.
The plan includes a 20% net reduction in non-commercial and non-medical headcount, primarily at its Netherlands headquarters, and targets 15% lower total G&A or approximately $10 million annually. The company expects one-time restructuring costs of about $7 million to be recorded in Q4 2025. Pharming said it consulted with its Dutch Works Council in line with Dutch labor law.
Pharming Group (NASDAQ:PHAR) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for leniolisib (Joenja®) with Priority Review status. The application seeks approval for treating children aged 4-11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
The sNDA is supported by positive data from a Phase III study showing improvements in lymphadenopathy and increased naïve B cells over 12 weeks. The FDA has set a PDUFA target date of January 31, 2026. If approved, leniolisib would become the first treatment available for APDS patients under 12 years old globally. The drug is already approved for patients 12 years and older since March 2023.
Pharming Group (Euronext: PHARM; Nasdaq: PHAR) announced its promotion from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective September 22, 2025. The AMX index consists of 25 companies selected based on free-float market capitalization and liquidity.
This promotion marks Pharming's return to the AMX index and reflects the company's strong growth momentum. CEO Fabrice Chouraqui emphasized that this inclusion will enhance the company's visibility and attractiveness to investors as they continue developing into a leading global rare disease company.
Pharming Group (Nasdaq: PHAR) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York, scheduled for September 8-10, 2025. CEO Fabrice Chouraqui will deliver a presentation on Monday, September 8 at 1:30pm EDT/19:30 CEST.
Investors can access the live webcast and replay through Pharming's website in the "Upcoming Events" and "News" sections. One-on-one meetings with management can be arranged through Investor Relations or H.C. Wainwright representatives.
Pharming Group (NASDAQ: PHAR) has appointed Kenneth Lynard as its new Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global leadership experience in the life sciences industry, with significant expertise in financial and operational transformation.
Lynard's most recent roles include CFO positions at Schoeller Allibert and Zentiva. Notably, during his five-year tenure at Gilead Sciences as Senior VP and CFO of Global Commercial Operations, R&D and Manufacturing, he helped triple the business following the Pharmasset acquisition. His appointment follows Pharming's strong first half 2025 results and aims to strengthen the company's financial leadership as it pursues its vision of becoming a leading global rare disease company.
Pharming Group (NASDAQ:PHAR) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, USA. CEO Fabrice Chouraqui will deliver a presentation on Tuesday, August 12, 2025, at 12:00 PM EDT/18:00 CEST.
Investors interested in one-on-one meetings with Pharming's management team can arrange them through the company's Investor Relations team or their Canaccord Genuity representative.
